Stephanie Tozzo
Chief Tech/Sci/R&D Officer at Avilar Therapeutics, Inc.
Net worth: - $ as of 2024-03-30
Profile
Stephanie Tozzo currently works at Avilar Therapeutics, Inc., as Chief Science Officer & Senior Vice President from 2021.
Dr. Tozzo also formerly worked at CohBar, Inc., as Director from 2022 to 2023.
Dr. Tozzo received her graduate degree from Université Paris-Saclay.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
COHBAR INC
-.--% | 2023-08-14 | 0 ( -.--% ) | - $ | 2024-03-30 |
Stephanie Tozzo active positions
| Companies | Position | Start |
|---|---|---|
Avilar Therapeutics, Inc.
 Avilar Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Avilar Therapeutics is an American biopharmaceutical company that specializes in the discovery and development of extracellular protein degraders. The company is based in an undisclosed location. The company has developed a proprietary discovery platform that includes novel, high-affinity, small molecule asgpr ligands and advanced modeling of the biophysics, pharmacokinetics, and pharmacodynamics of atac mediated endocytosis and degradation. Avilar is developing atacs, a new class of protein degraders that shuttle disease-causing proteins from circulation to the endolysosome where the unwanted proteins are degraded. The company is leveraging their atac platform to create a broad and diverse pipeline of first-in-class extracellular protein degraders. The company was founded by Nathaniel Brooks Horwitz and Jamie Kasuboski. The CEO is Daniel S. Grau. | Chief Tech/Sci/R&D Officer | 2021-10-31 |
Former positions of Stephanie Tozzo
| Companies | Position | End |
|---|---|---|
| COHBAR, INC. | Director/Board Member | 2023-11-09 |
Training of Stephanie Tozzo
| Université Paris-Saclay | Graduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| COHBAR, INC. | Health Technology |
| Private companies | 1 |
|---|---|
Avilar Therapeutics, Inc.
Avilar Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Avilar Therapeutics is an American biopharmaceutical company that specializes in the discovery and development of extracellular protein degraders. The company is based in an undisclosed location. The company has developed a proprietary discovery platform that includes novel, high-affinity, small molecule asgpr ligands and advanced modeling of the biophysics, pharmacokinetics, and pharmacodynamics of atac mediated endocytosis and degradation. Avilar is developing atacs, a new class of protein degraders that shuttle disease-causing proteins from circulation to the endolysosome where the unwanted proteins are degraded. The company is leveraging their atac platform to create a broad and diverse pipeline of first-in-class extracellular protein degraders. The company was founded by Nathaniel Brooks Horwitz and Jamie Kasuboski. The CEO is Daniel S. Grau. | Commercial Services |
- Stock Market
- Insiders
- Stephanie Tozzo
